CLCS (Cell Source) Shiller PE Ratio: (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLCS Cell Source Inc CLCS
35 GF Score
Price $0.65
View Full Analysis

What is Cell Source Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cell Source  (OTCPK:CLCS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cell Source Shiller PE Ratio Related Terms


Cell Source Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Cell Source's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Shiller PE Ratio Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CLCS vs EDSA, CTXR, ASBP: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Cell Source's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cell Source's Shiller PE Ratio falls into.


CLCS
35GF Score
Cell Source Inc CLCS
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cell Source's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Cell Source's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.01/315.6050*315.6050
=-0.010

Current CPI (Dec. 2024) = 315.6050.

Cell Source Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.020 236.119 -0.027
201506 -0.020 238.638 -0.026
201509 -0.030 237.945 -0.040
201512 -0.030 236.525 -0.040
201603 -0.030 238.132 -0.040
201606 -0.030 241.018 -0.039
201609 -0.030 241.428 -0.039
201612 0.050 241.432 0.065
201703 -0.040 243.801 -0.052
201706 -0.030 244.955 -0.039
201709 -0.020 246.819 -0.026
201712 -0.020 246.524 -0.026
201803 -0.030 249.554 -0.038
201806 -0.020 251.989 -0.025
201809 -0.020 252.439 -0.025
201812 -0.020 251.233 -0.025
201903 -0.060 254.202 -0.074
201906 -0.040 256.143 -0.049
201909 -0.060 256.759 -0.074
201912 -0.020 256.974 -0.025
202003 -0.040 258.115 -0.049
202006 -0.050 257.797 -0.061
202009 -0.050 260.280 -0.061
202012 -0.060 260.474 -0.073
202103 -0.050 264.877 -0.060
202106 -0.050 271.696 -0.058
202109 -0.060 274.310 -0.069
202112 -0.030 278.802 -0.034
202203 -0.050 287.504 -0.055
202206 -0.040 296.311 -0.043
202209 -0.040 296.808 -0.043
202212 -0.040 296.797 -0.043
202303 -0.050 301.836 -0.052
202306 -0.040 305.109 -0.041
202309 -0.040 307.789 -0.041
202312 -0.030 306.746 -0.031
202403 -0.040 312.332 -0.040
202406 -0.040 314.175 -0.040
202409 -0.040 315.301 -0.040
202412 -0.010 315.605 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price